August Bioservices Closes $23 6 Million Series A Extension to Expand U S Biopharma Manufacturing Capabilities streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
August Bioservices, a Nashville, Tenn.-based contract development and manufacturing organization (CDMO) providing drug discovery, development, and pharmaceutical manufacturing services, closed a $23.6m Series A extension.
The round was led by Polaris Partners, who joined existing investor Oak HC/FT. As part of the financing, Brian Chee, Managing Partner of Polaris Partners, joined the August Bioservices’ board as a Director. Darren Carroll of Polaris Partners joined the board as an observer.
The company intends to use the funds to expand its manufacturing capacity and capabilities to advance the technology platforms needed to support production of sterile injectable medications.
Led by Jenn Adams, CEO, August Bioservices partners with biopharmaceutical and biotech companies to provide a wide array of services to accelerate the advancement of novel therapeutics along the drug development pathway. Its service portfolio includes cGMP non-sterile and bulk manufacturing, aseptic fil
High-Throughput Clonogenic Potential Assays
An essential part of the drug discovery process is to determine a living cell’s ability to survive and proliferate in response to an external stimulus. The clonogenic potential assay is an established technique that effectively, accurately, and quickly measures this response to gene knockdown or overexpression, cytotoxic treatment, radiation treatment or a combination of the three. Traditional assays are difficult and time consuming because of the need to manually count colonies using a stereo microscope, this leads to an increased probability of user error and inconsistency.
August Bioservices has the expertise to apply the powerful BioTek Cytation 5 Multi-Mode Imager, capable of imaging and analyzing cell-based assays in an automated and high throughput way.
Eliminate Drug Discovery Errors Before They Happen – Why Picking The Correct Binding Technology Is Critical To Success
August Bioservices has the seasoned expertise and a cutting edge and comprehensive toolbox of binding technologies to help you chart the best course for your drug discovery exploration. Starting with the right tool – to ascertain a quick and decisive “go/no go” decision – is crucial in saving you time and money in the drug development process.
These five case studies is your Binding Technologies Toolbox, covering the topics of Temperature Related Intensity Change (TRIC), Surface Plasmon Resonance (SPR), Differential Scanning Fluorimetry (DSF), and Isothermal Titration Calorimetry (ITC).